Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Mini Review
  • Published:

Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment

Bone Marrow Transplantation volume 31, pages 1–10 (2003)Cite this article

Summary:

Hematopoietic progenitor cell transplantation is often associated with severe mucosal toxicity. The need for parenteral analgesics and parenteral nutrition are evidence of the severity of the problem in individual patients. However, the increased risk for systemic infection related to bacteremia associated with the breakdown of mucosal barriers is a significant cause of morbidity and mortality as well. There is a multitude of grading scales, demonstrating the lack of consensus among clinicians in this area. Multiple agents have been used prophylactically and therapeutically to address mucositis. While efforts have been less successful in the past, the advent of newer agents including amifostine, keratinocyte growth factor, transforming growth factor beta and interleukin-11 provides hope that this toxicity will be significantly decreased in the near future.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Sonis ST, Oster G, Fuchs H et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001; 19: 2201–2205.

    Article  CAS  Google Scholar 

  2. Schubert MM, Peterson DE, Lloid ME . Oral complications. In: Thomas KG, Forman Blume SJ (eds). Hematopoietic Stem Cell Transplantation, 2nd edn. Blackwell Science: Malden, MA, 1999.

    Google Scholar 

  3. Rapoport AP, Miller Watelet LF, Linder T et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol 1999; 17: 2446–2453.

    Article  CAS  Google Scholar 

  4. Morgan RJ, Doroshow JH, Leong L et al. Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer. Bone Marrow Transplant 2001; 28: 859–863.

    Article  CAS  Google Scholar 

  5. Moreau P, Facon T, Attal M et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731–735.

    Article  CAS  Google Scholar 

  6. Stiff P . Mucositis associated with stem cell transplantation: current status and innovative approaches to management. Bone Marrow Transplant 2001; 27 (Suppl. 2): S3–S11.

    Article  Google Scholar 

  7. Sonis ST . Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 1998; 34: 39–43.

    Article  CAS  Google Scholar 

  8. Sezer O, Eucker J, Metzner B et al. Mucositis is associated with increased rate of documented infections and treatment related mortality after high-dose therapy with autologous peripheral stem-cell transplantation. Proc ASCO 2000; (abstr. 216).

  9. Ruescher TJ, Sodeifi A, Scrivani SJ et al. The impact of mucositis on α-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998; 82: 2275–2281.

    Article  CAS  Google Scholar 

  10. Avigan D, Richardson P, Elias A et al. Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors: a case series with a review of the literature. Cancer 1998; 83: 409–414.

    Article  CAS  Google Scholar 

  11. U.S. Department of Health and Human Services. Oral Health in America: a report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, National Institutes of Dental and Craniofacial Research, National Institutes of Health, 2000.

  12. Miller AB, Hoogstraten B, Staquet M, Winkler A . Reporting results of cancer treatment. Cancer 1981; 47: 207–214.

    Article  CAS  Google Scholar 

  13. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–216.

    Article  CAS  Google Scholar 

  14. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655.

    Article  CAS  Google Scholar 

  15. Sonis ST, Eilers JP, Epstein JB et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Cancer 1999; 85: 2103–2113.

    Article  CAS  Google Scholar 

  16. Eilers J, Berger AM, Peterson MC . Development, testing and application of the Oral Assessment Guide. Oncol Nurs Forum 1988; 15: 325–330.

    CAS  PubMed  Google Scholar 

  17. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562–1568.

    Article  CAS  Google Scholar 

  18. Bearman SI, Appelbaum FR, Back A et al. Regimen-related toxicity and early post transplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 1989; 7: 1288–1294.

    Article  CAS  Google Scholar 

  19. Anonymous. Development of a staging system for chemotherapy induced stomatitis. Western Consortium for Cancer Nursing Research. Cancer Nurs 1991; 14: 6–12.

  20. Khan SA, Wingard JR . Infection and mucosal injury in cancer. J Natl Cancer Inst Monogr 2001; 21: 31–36.

    Article  Google Scholar 

  21. Mahood DJ, Dose AM, Loprinzi CL et al. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol 1991; 9: 449–452.

    Article  CAS  Google Scholar 

  22. Cascinu S, Fedeli A, Fedeli SL et al. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Oral Oncol Eur J Cancer 1994; 30B: 234–236.

    Article  CAS  Google Scholar 

  23. Roche LK, Loprinzi CL, Lee JK et al. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer 1993; 72: 2234–2238.

    Article  Google Scholar 

  24. Weisdorf DJ, Bostrom B, Raether D et al. Oropharyngeal mucositis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouth rinse. Bone Marrow Transplant 1989; 4: 89–95.

    CAS  Google Scholar 

  25. Symonds RP, McIlroy P, Khorrami J et al. The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. Br J Haematol 1996; 74: 312–317.

    CAS  Google Scholar 

  26. Okumo SH, Foote RL, Loprinzi CL et al. A randomized trial of nonabsorbable antibiotic lozenge given to alleviate radiation induced mucositis. Cancer 1997; 79: 2193–2199.

    Article  Google Scholar 

  27. Dodd MJ, Dibble SL, Miaskowski C et al. Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy induced mucositis. Oral Surg Oral Med Oral Pathol Oral Rad Endod 2000; 90: 39–47.

    Article  CAS  Google Scholar 

  28. Fox AD, Kripke SA, DePaula J et al. Effect of a glutamine-supplemented enteral diet on methotrexate-induced enterocolitis. J Parenter Enteral Nutr 1988; 12: 325–331.

    Article  CAS  Google Scholar 

  29. Ziegler TR . Glutamine supplementation in cancer patients receiving bone marrow transplantation and high dose chemotherapy. J Nutr 2001; 131: 2578S–2584S.

    Article  CAS  Google Scholar 

  30. Souba WW, Klimberg VS, Plumley DA et al. Current research review: the role of glutamine in maintaining a healthy gut and supporting the metabolic response to injury and infection. J Surg Res 1990; 48: 383–391.

    Article  CAS  Google Scholar 

  31. Anderson PM, Schroeder G, Skubitz KM . Oral glutamine reduces the duration and severity of stomatitis after cytotoxic chemotherapy. Cancer 1998; 83: 1433–1439.

    Article  CAS  Google Scholar 

  32. Cockerham MB, Weinberger BB, Lerchie SB . Oral glutamine for the prevention of oral mucositis associated with high dose paclitaxel and melphalan for autologous bone marrow transplantation. Ann Pharmacother 2000; 34: 300–303.

    Article  CAS  Google Scholar 

  33. Coghlin Dickson TM, Wong RM, Offrin RS et al. Effect of oral glutamine supplementation during bone marrow transplantation. J Parenter Enteral Nutr 2000; 24: 61–66.

    Article  CAS  Google Scholar 

  34. Schloerb PR, Skikne BS . Oral and parenteral glutamine in bone marrow transplantation: a randomized, double-blind study. J Parenter Enteral Nutr 1999; 23: 117–122.

    Article  CAS  Google Scholar 

  35. Anderson PM, Ramsay NKC, Shu XO et al. Effect of low dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplant 1998; 22: 339–344.

    Article  CAS  Google Scholar 

  36. Attal M, Huquet F, Rubie H et al. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial. Blood 1993; 83: 732–736.

    Google Scholar 

  37. Bianc JA, Appelbaum FR, Neumatis J et al. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991; 78: 1205–1211.

    Google Scholar 

  38. Hancock GE, Kaplan G, Cohn ZA . Keratinocyte growth regulation by the products of immune cells. J Exp Med 1988; 168: 1395–1402.

    Article  CAS  Google Scholar 

  39. Bussolino F, Wang JM, Defilippi P et al. Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature 1989; 337: 471–473.

    Article  CAS  Google Scholar 

  40. Vyalov S, Desmouliere A, Gabbiani G . GM-CSF-induced granulation tissue formation: relationships between macrophage and myofibroblast accumulation. Virchows Arch B Cell Pathol 1993; 63: 231–239.

    Article  CAS  Google Scholar 

  41. Kucukcelebi A, Carp SS, Hayward PG . Granulocyte–macrophage colony-stimulating factor reverses the inhibition of wound contraction caused by bacterial contamination. Wounds 1992; 4: 241–247.

    Google Scholar 

  42. Jyung RW, Wu L, Pierce GF, Mustoe TA . Granulocyte–macrophage colony-stimulating factor and granulocyte colony-stimulating factor: differential action on incisional wound healing. Surgery 1994; 115: 325–334.

    CAS  PubMed  Google Scholar 

  43. Neumanitis J, Rosenfeld C, Ash R et al. Phase III randomized, double-blind placebo controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 949–954.

    Google Scholar 

  44. Gordon B, Spadinger A, Hodges E et al. Effect of granulocyte–macrophage colony-stimulating factor on oral mucositis after hematopoietic stem cell transplantation. J Clin Oncol 1994; 12: 1917–1922.

    Article  CAS  Google Scholar 

  45. Legros M, Fleury J, Bay JO et al. RhGM-CSF vs placebo following rhGM-CSF mobilized PBPC transplantation: a phase II double-blind randomized trial. Bone Marrow Transplant 1997; 19: 209–213.

    Article  CAS  Google Scholar 

  46. Atkinson K, Biggs JC, Downs K et al. GM-CSF after allogeneic bone marrow transplantation: accelerated recovery of neutrophils. monocytes and lymphocytes. Aust N Z J Med 1991; 21: 686–692.

    Article  CAS  Google Scholar 

  47. Evans G, Mahendra P, Brightwell M et al. A double blind randomised trial of oral GM-CSF mouthwash versus placebo in the treatment of mucositis following PBSC/bone marrow transplantation. Bone Marrow Transplant 1998; 21 (Suppl. 1): S88 (abstr. 310).

    Google Scholar 

  48. van der Lelie J, Thomas L, Van Oers M et al. Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo controlled double blind study. Blood 1999; 94 (Suppl. 1): 363b (abstr. 4849).

    Google Scholar 

  49. Ovila-Martinez R, Rubio ME, Borbolla JR et al. GM-CSF mouthwashes as treatment for mucositis in BMT patients. Blood 1994; 84 (Suppl. 1): 717a (abstr. 2853).

    Google Scholar 

  50. Bez C, Demarosi F, Sardella A et al. GM-CSF mouthrinses in the treatment of severe oral mucositis. Oral Surg Oral Med Oral Pathol Oral Rad Endod 1999; 88: 311–315.

    Article  CAS  Google Scholar 

  51. Castagna L, Benhamou E, Pedraza E et al. Prevention of mucositis in bone marrow transplantation: a double blind randomised controlled trial of sucralfate. Ann of Oncol 2001; 12: 953–955.

    Article  CAS  Google Scholar 

  52. Parry TJ, Fikes JD . Repifermin (keratinocyte growth factor-2) promotes mucosal hyperplasia throughout the alimentary tract in normal monkeys. Biol Blood Marrow Transplant 2001; 7: 84 (abstr. 76).

    Google Scholar 

  53. Okunieff P, Li M, Liu W et al. Keratinocyte growth factors radioprotect bowel and bone marrow but not KHT sarcoma. Am J Clin Oncol 2001; 24: 491–495.

    Article  CAS  Google Scholar 

  54. Connolly KM, Alderson R, Vance C et al. Efficacy of Repifermin (keratinocyte growth factor-2) in models of intestinal injury: lack of oncogenic activity. Proc ASCO 2001 (abstr. 2956).

  55. Meropol NJ, Gutheil J, Pelley R et al. Keratinocyte growth factor (KGF) as a mucositis protectant: a randomized phase I trial. Proc ASCO 2000; (abstr. 2374).

  56. Freytes C, LeVeque F, Meisenberg B et al. Safety and efficacy of repifermin (KGF-2) in reducing mucositis in patients undergoing autologous hematopoietic stem cell transplantation (auto-HSCT) – results of a phase 2a trial. Blood 2001; 98 (suppl 1a): 346b, (abstr. 5154).

    Google Scholar 

  57. Min D, Taylor P, Chung B et al. Protection from thymic epithelial cell (TEC) injury by pre-BMT keratinocyte growth factor (KGF): a new approach to speed thymic reconstitution after lethal irradiation. Blood 2000; 96 (Suppl. 1): 474a (abstr. 2039).

    Google Scholar 

  58. Krijanovski OI, Hill GR, Cooke KR et al. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood 2000; 94: 825–831.

    Google Scholar 

  59. Giles FJ, Redman R, Yazji S, Bellm L . Iseganan HCl: a novel antimicrobial agent. Expert Opin Investig Drugs 2002; 11: 1161–1170.

    Article  CAS  Google Scholar 

  60. Goldberg SL, Pineiro L, Schuster MW et al. Randomized vehicle controlled study of Immunol oral rinse for the prevention of oral mucositis in bone marrow transplant patients undergoing intensive chemotherapy and/or radiotherapy. Blood 2001; 98: 854a (abstr. 3547).

    Google Scholar 

  61. Goldberg SL, Pineiro L, Schuster MW et al. Prevention of mucositis by Immunol oral rinse: final results of a randomized, vehicle controlled study. Biol Blood Marrow Transplant 2002; 8: 74 (abstr. 45).

    Google Scholar 

  62. Berl T, Schwertschlag U . Preclinical pharmacologic basis for clinical use of rhIL-11 as an effective platelet support agent. Oncology 2000; 14 (Suppl. 8): 12–20.

    CAS  PubMed  Google Scholar 

  63. Du XX, Doerschuk CM, Orazi A et al. A bone marrow stromal-derived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy. Blood 1994; 83: 33–37.

    CAS  Google Scholar 

  64. Trepicchio WL, Ozawa M, Walters IB et al. Interleukin-11 therapy selectively downregulates type 1 cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 1999; 104: 1527–1537.

    Article  CAS  Google Scholar 

  65. Schwerkoske J, Schwartzberg L, Weaver CH et al. A phase 1 double-masked, placebo-controlled study to evaluate tolerability of neumega® (rhIL-11; Oprelvekin) to reduce mucositis in patients with solid tumors or lymphoma receiving high-dose chemotherapy (CT) with autologous peripheral blood stem cell reinfusion (PBSCT). Proc ASCO 1999, (abstr. 2256).

  66. Capizzi RL . The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Sem Oncol 1999; 26: 3–21.

    CAS  Google Scholar 

  67. Valeriote F, Tolen S . Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res 1982; 42: 4330–4331.

    CAS  PubMed  Google Scholar 

  68. Douay L, Hu C, Giarratana MC et al. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging. Blood 1995; 86: 2849–2855.

    CAS  Google Scholar 

  69. Treskes M, Boven E, van de Loosdrecht AA et al. Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice. Eur J Cancer 1994; 30: 183–187.

    Article  Google Scholar 

  70. Yuhas JM, Culo F . Selective inhibition of the nephrotoxicity of cisdichlorodiammineplatinum (II) by WR-2721 without altering its antitumor properties. Cancer Treat Rep 1980; 64: 57–64.

    CAS  PubMed  Google Scholar 

  71. Yuhas JM . Differentiated protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine. Cancer Treat Rep 1979; 63: 971–976.

    CAS  PubMed  Google Scholar 

  72. McDonald S, Meyerowitz C, Smudzin T, Rubin P . Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys 1994; 29: 747–754.

    Article  CAS  Google Scholar 

  73. Davidson DE, Grenan MM, Sweeney TR . Biological characteristics of some improved radioprotectors. In: Brady LW (ed). Radiation Sensitizers: Their Use in the Clinical Management of Cancer. Masson Publishing: New York, 1980: 309.

    Google Scholar 

  74. Buntzel J, Kutner K, Frohlich D, Glatzel M . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol 1998; 9: 505–509.

    Article  Google Scholar 

  75. Liu T, Liu Y, He S et al. Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 1992; 69: 2820–2825.

    Article  CAS  Google Scholar 

  76. Brizel DM, Wasserman TH, Henke M et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000; 18: 3339–3345.

    Article  CAS  Google Scholar 

  77. Flomenberg N, Garcia-Manero G, Grosso D et al. High CR rate and normal organ cytoprotection using dose escalation of idarubicin with amifostine in high risk patients with AML (abstract 37) Proc ASCO 2000; 19: 12a.

    Google Scholar 

  78. Phillips GL, Meisenburg B, Hale GA, et al. Amifostine (AF) cytoprotection (CP) of escalating doses of melphalan (MEL) and autologous hematopoietic stem cell transplantation (AHSCT): final results of a phase 1 II study (abstract 24). Proc ASCO 2001; 20: 7a.

    Google Scholar 

  79. Capelli D, Santini G, DeSouza C et al. Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study. Br J Haematol 2000; 110: 300–307.

    Article  CAS  Google Scholar 

  80. Sonis ST, Van Vugt AG, O’Brien JP et al. Transforming Growth Factor-β3 mediated modulation of cell cycling and attenuation of 5-fluoruracil induced oral mucositis. Oral Oncol 1997; 33: 47–54.

    Article  CAS  Google Scholar 

  81. Wymenga ANM, van der Graaf WTA, Hofstra LS et al. Phase I study of transforming growth factor-β3 mouthwashes for prevention of chemotherapy-induced mucositis. Clin Cancer Res 1999; 5: 1363–1368.

    CAS  PubMed  Google Scholar 

  82. Cowen D, Tardieu C, Schubert M et al. Low energy helium-neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial. Int J Radiat Onc Biol Phys 1997; 38: 697–703.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematologic Malignancies, Blood & Marrow Transplant Program, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA

    J Filicko & N Flomenberg

  2. Department of Medicine, Comprehensive Cancer Center of the Uiversity Hospitals of Cleveland/Case Western Reserve University, Cleveland, OH, USA

    H M Lazarus

Authors
  1. J Filicko
    View author publications

    Search author on:PubMed Google Scholar

  2. H M Lazarus
    View author publications

    Search author on:PubMed Google Scholar

  3. N Flomenberg
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Filicko, J., Lazarus, H. & Flomenberg, N. Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment. Bone Marrow Transplant 31, 1–10 (2003). https://doi.org/10.1038/sj.bmt.1703776

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703776

Keywords

This article is cited by

Search

Advanced search

Quick links